Valproate competes with palmitate for binding to serum albumin.
Addition of sodium valproate (VPA) to a buffered solution of human serum albumin (HSA) or to serum reduces binding affinity for palmitate. A maximal pharmacologic VPA concentration, 700 microM, added to a 300-microM albumin solution, reduces the reserve albumin concentration for binding of palmitate by a factor of 0.64. One possible site model explaining these findings may be that VPA competes strongly with one among three palmitate molecules, bound to albumin with high affinity, and induces a weaker displacement of a second palmitate.
Vorum
H
H
Institute of Medical Biochemistry, University of Aarhus, Denmark.
Andersen
S
S
Brodersen
R
R
D001667:Binding, Competitive; D006801:Humans; D009994:Osmolar Concentration; D010168:Palmitates / Q000378:metabolism*; D010169:Palmitic Acids / Q000378:metabolism*; D012709:Serum Albumin / Q000378:metabolism*; D014635:Valproic Acid / Q000378:metabolism*
D010168:Palmitates; D010169:Palmitic Acids; D012709:Serum Albumin; D014635:Valproic Acid